US 11,905,283 B2
Compounds and compositions for inhibiting the activity of SHP2
Zhuoliang Chen, Belmont, MA (US); Jorge Garcia Fortanet, Wilmington, MA (US); Rajesh Karki, Quincy, MA (US); Matthew J. Lamarche, Reading, MA (US); Dyuti Majumdar, Cambridge, MA (US); Lawrence Blas Perez, Silver Spring, MD (US); Martin Sendzik, Belmont, MA (US); Troy Douglas Smith, Nashua, NH (US); Fan Yang, West Roxbury, MA (US); and Bing Yu, Belmont, MA (US)
Assigned to NOVARTIS AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Dec. 22, 2020, as Appl. No. 17/130,374.
Application 17/130,374 is a division of application No. 16/309,076, granted, now 10,934,285, previously published as PCT/IB2017/053469, filed on Jun. 12, 2017.
Claims priority of provisional application 62/349,697, filed on Jun. 14, 2016.
Prior Publication US 2021/0300919 A1, Sep. 30, 2021
Int. Cl. C07D 471/04 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 455/02 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 455/02 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01)] 8 Claims
 
1. A compound of formula II:

OG Complex Work Unit Chemistry
in which:
R1 is selected from:

OG Complex Work Unit Chemistry
R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a ring selected from piperidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl and pyrrolidinyl; wherein said pyrrolidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl or piperidinyl is unsubstituted or substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, methyl-amino, hydroxyl, cyano, fluoro-methyl, fluoro and ((((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)amino)methyl;
R4 is selected from hydroxyl, C1-3alkoxy and OC(O)C1-3 alkyl;
R5 is selected from H and methyl;
R6 is selected from hydrogen, methyl and phenyl;
R7 is selected from hydrogen, methyl, ethyl, phenyl and benzyl;
R8 is selected from hydrogen and methyl;
Y1 is selected from N and CH;
Y2 is selected from N and CH;
Y3 is selected from NH and CH2;
Y4 is selected from N and CH;
Y5 is selected from N and CH; or a pharmaceutically acceptable salt thereof.